Thursday, January 10, 2008

Amgen Statement on Alzheimer's Case Study

A study titled “Rapid Cognitive Improvement in Alzheimer’s Disease Following Perispinal Etanercept Administration” was published this week in the Journal of Neuroinflammation.  It is important to note that the study published was a case study involving a single patient.  This study was not supported nor endorsed by Amgen. While Amgen and others have long recognized the potential for tumor necrosis factor (TNF) inhibitors to have an effect on neurological conditions, we have carefully examined this study and believe that at this time there is insufficient scientific data to support the use of a TNF inhibitor as a means of treating Alzheimer’s disease.  Amgen will continue to review data on the use of Enbrel® (etanercept) and other anti-inflammatory agents for the treatment of Alzheimer’s disease. 

Posted in